Trial Profile
Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jun 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Pioglitazone (Primary) ; Bosutinib; Dasatinib; Imatinib; Nilotinib; Ponatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ACTIW
- 06 Aug 2020 Planned End Date changed from 1 Jun 2021 to 1 Jun 2023.
- 06 Aug 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Nov 2022.
- 23 May 2018 Avelumab has been added in the treatments.